Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Energy
- Branch
- Not reported
- Recipient company
- LYNNTECH INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- PMVAL8J63516
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
60583 A recent advance in high-throughput genomic technologies has led to the development of methods for whole-genome sequencing and for the establishment of comprehensive mRNA expression maps. However, no equivalent technology is currently available for the rapid analysis of proteins and/or large toxicological molecules that are important as effector molecules in biological control or drug development. This project will develop a portable, versatile analyzer for automated, high-throughput analysis of clinically important drugs and proteins in biological fluids such as blood and urine. The approach is based on new micro/nano fluidics technology that can be used to analyze large biomolecules in complex sample matrices, combining molecular recognition and signal transduction in a single element. Phase I demonstrated highly specific recognition of large protein molecules using two new types of molecularly imprinted polymers (MIP). A unique electrical signal transduction system was developed to sense the specific binding interactions between the analyte molecule and the MIP sensing element. Phase II will optimize the MIPs affinity toward selected, clinically important drugs and proteins, and develop protocols for their detection in biological fluids. Phase II also will provide optimization and testing of the design and fabrication of a prototype, micro/nano fluidic device capable of analyzing multiple samples and multiple proteins using an array of sensing elements /tranducers. Commercial Applications and Other Benefits as described by the awardee: A detection system for sensing/recognition of proteins and/or toxicological drugs in complex biological samples should lead to a portable, low cost, and simple to use instrument for point-of-care clinical diagnostics. Potential commercial applications should include therapeutical drug development, medical toxicology, clinical diagnostics, forensics, food, and environmental analysis.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
1,079 SBIR/STTR records share this UEI (1988–2025). Reported award amounts total $327,411,388. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy, National Science Foundation, Environmental Protection Agency
Agency intelligence
Department of Energy
Back to SBIR/STTR Research Awards